Business
SNGX: Dusquetide (SGX945) Granted Orphan Drug Designation for Behcet’s Disease
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Dusquetide (SGX945) Granted Orphan Drug Designation for the Treatment of Behcet’s Disease On August 18, 2025, Soligenix, Inc., (NASDAQ:SNGX) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to dusquetide, the active ingredient in SGX945, for “treatment of Behcet’s
About this update from Soligenix, Inc.
[{"type":"text","content":"By David Bautz, PhD","length":19,"tagName":"p"},{"type":"text","content":"NASDAQ:SNGX","length":11,"tagName":"p"},{"type":"text","content":"READ THE FULL SNGX RESEARCH REPORT","length":34,"tagName":"p"},{"type":"text","content":"Business Update","length":15,"tagName":"p"},{"type":"text","content":"Dusquetide (SGX945) Granted Orphan Drug Designation for the Treatment of Behcet’s Disease","length":89,"tagName":"p"},{"type":"text","content":"On August 18, 2025, Soligenix, Inc., (NASDAQ:SNGX) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to dusquetide, the active ingredient in SGX945, for “treatment of Behcet’s Disease”. This designation comes following the release of highly encouraging Phase 2a data for SGX945 in Behcet’s Disease (BD) in which SGX945 exhibited biological efficacy.","length":400,"tagName":"p"},{"type":"text","content":"The Phase 2a study was modeled after the Phase 3 clinical trial of apremilast (Otezla®), which served as the basis for marketing approval of that drug for oral ulcers in BD (Hatemi et al., 2019). A total of eight patients were enrolled in the study and administered SGX945 IV twice a week for four weeks. A four-week follow-up was also conducted following cessation of SGX945 treatment. The primary endpoint was the area under the curve (AUC) of the mean number of ulcers versus time.","length":484,"tagName":"p"},{"type":"text","content":"The results of the trial showed that after 4 weeks of treatment, the SGX945-treated group had a 40% improvement relative to the placebo group from the Phase 3 apremilast study. This compares to a 37% improvement for the apremilast group relative to placebo. The improvement in the SGX945-treated group was sustained through the 4-week follow-up period. A 32% improvement relative to placebo was noted at Week 8, even though treatment had stopped at Week 4. Apremilast-treated patients, who were administered drug continuously through Week 12, showed a 41% improvement at Week 8.","length":578,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":581,"height":447,"url":"https://media.zenfs.com/en/scr.zacks.com/f624ec6e3d1aeb638661be296008a824"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g3fjcF9zYRe8nA97ObFPvA--/YXBw...